Bolt Biotherapeutics, Inc. (BOLT)
6.54
+0.16
(+2.51%)
USD |
NASDAQ |
Nov 06, 16:00
6.50
-0.04
(-0.61%)
After-Hours: 20:00
Bolt Biotherapeutics Research and Development Expense (Quarterly) : 4.978M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 4.978M |
| March 31, 2026 | 4.626M |
| December 31, 2025 | 4.733M |
| September 30, 2025 | 6.245M |
| June 30, 2025 | 7.151M |
| March 31, 2025 | 9.113M |
| December 31, 2024 | 11.30M |
| September 30, 2024 | 13.34M |
| June 30, 2024 | 14.98M |
| March 31, 2024 | 16.07M |
| December 31, 2023 | 15.82M |
| September 30, 2023 | 14.49M |
| June 30, 2023 | 14.46M |
| March 31, 2023 | 13.44M |
| Date | Value |
|---|---|
| December 31, 2022 | 15.68M |
| September 30, 2022 | 17.85M |
| June 30, 2022 | 17.84M |
| March 31, 2022 | 16.86M |
| December 31, 2021 | 21.58M |
| September 30, 2021 | 18.27M |
| June 30, 2021 | 18.81M |
| March 31, 2021 | 13.32M |
| December 31, 2020 | 14.10M |
| September 30, 2020 | 8.894M |
| June 30, 2020 | 8.597M |
| March 31, 2020 | 6.26M |
| December 31, 2019 | 6.927M |
| September 30, 2019 | 5.793M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Caribou Biosciences, Inc. | 21.35M |
| Arrowhead Pharmaceuticals, Inc. | 192.06M |
| Oncolytics Biotech, Inc. | 4.262M |
| Sangamo Therapeutics, Inc. | 26.57M |
| Sarepta Therapeutics, Inc. | 82.55M |